Mancini Marianna
SEC CIK 1838112 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | COO | 422.8K | — | $32.19M | 35 | 2021-09-28 | 2026-07-29 |
Most active insiders at VKTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lian Brian | Pres, CEO, Dir | — | $14.01M |
| 2 | ZANTE GREG | CFO | — | $2.82M |
| 3 | Mancini Marianna | COO | — | $2.73M |
| 4 | Rowland Charles A Jr | Dir | — | $2.13M |
| 5 | FOEHR MATTHEW W | Dir | — | $561.8K |
| 6 | Aubuchon Neil William | Chief Commercial Off | $149.9K | — |
| 7 | Kelly-Gemmell Dorothy Elizabeth | Dir | — | — |
| 8 | Rouan Sarah Kathryn | Dir | — | — |
| 9 | MACARTNEY LAWSON | Dir | — | — |
| 10 | SINGLETON J MATTHEW | Dir | — | — |
Transactions 35
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 20:06 | 2026-07-28 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +31.7K | 441.0K | +8% | $0 | |
| 2026-07-29 20:06 | 2026-07-29 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $33.47 | -18.2K | 422.8K | -4% | -$609.6K | |
| DM | 2026-01-05 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +73.0K | 466.9K | +19% | $0 |
| DM | 2026-01-05 | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $32.97 | -57.7K | 409.2K | -12% | -$1.90M |
| 2025-10-28 | 2025-10-27 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +11.1K | 388.7K | +3% | $0 | |
| 2025-10-28 | 2025-10-28 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $35.00 | -6,185 | 382.5K | -2% | -$216.5K | |
| 2025-07-03 | 2025-07-02 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +7,667 | 381.8K | +2% | $0 | |
| 2025-07-03 | 2025-07-03 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $27.77 | -4,266 | 377.5K | -1% | -$118.5K | |
| DM | 2025-01-06 | 2025-01-03 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +66.2K | 406.7K | +19% | $0 |
| DM | 2025-01-06 | 2025-01-06 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $42.75 | -54.2K | 374.1K | -13% | -$2.32M |
| M | 2024-07-31 | 2024-07-29 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +31.7K | 380.2K | +9% | $0 |
| M | 2024-07-31 | 2024-07-30 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $57.13 | -18.0K | 362.1K | -5% | -$1.03M |
| DM | 2024-05-02 | 2024-05-01 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | M - OptEx | $6.18 | +281.4K | 366.5K | +331% | +$1.74M |
| DM | 2024-05-02 | 2024-05-01 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale+OE | $78.66 | -281.4K | 354.8K | -44% | -$22.14M |
| 2024-03-27 | 2024-03-27 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $83.34 | -16.6K | 363.6K | -4% | -$1.38M | |
| 2024-03-27 | 2024-03-27 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +31.7K | 380.2K | +9% | $0 | |
| 2024-03-04 | 2024-03-01 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $85.22 | -17.0K | 348.5K | -5% | -$1.45M | |
| 2024-03-04 | 2024-03-01 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +31.7K | 365.5K | +9% | $0 | |
| DM | 2024-01-04 | 2024-01-03 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +98.3K | 380.7K | +35% | $0 |
| DM | 2024-01-04 | 2024-01-03+ | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $17.66 | -63.4K | 348.0K | -15% | -$1.12M |
| D | 2023-04-18 | 2023-04-17 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale+OE | $20.00 | -12.5K | 287.8K | -4% | -$250.0K |
| D | 2023-04-18 | 2023-04-17 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | M - OptEx | $13.07 | +12.5K | 300.3K | +4% | +$163.4K |
| DM | 2023-04-03 | 2023-03-30 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | M - OptEx | $12.56 | 0 | 261.9K | New | $0 |
| D | 2023-04-03 | 2023-03-30 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $17.57 | -30.8K | 287.8K | -10% | -$541.1K |
| D | 2023-04-03 | 2023-03-30 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +56.7K | 318.6K | +22% | $0 |
| DM | 2023-03-30 | 2023-03-28+ | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale+OE | $15.17 | -237.8K | 288.1K | -45% | -$3.61M |
| DM | 2023-03-30 | 2023-03-28+ | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | M - OptEx | $2.93 | +182.4K | 337.1K | +118% | +$534.1K |
| 2023-01-17 | 2023-01-15 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $8.95 | -1,079 | 317.3K | -0.3% | -$9,657 | |
| DM | 2023-01-04 | 2022-12-30+ | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +114.2K | 351.2K | +48% | $0 |
| DM | 2023-01-04 | 2022-12-30+ | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $8.74 | -45.6K | 260.5K | -15% | -$398.5K |
| 2022-02-11 | 2022-01-15 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $4.24 | -827 | 238.7K | -0.3% | -$3,506 | |
| DM | 2022-01-05 | 2022-01-03+ | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $4.68 | -15.8K | 174.0K | -8% | -$73.8K |
| D | 2022-01-05 | 2022-01-03 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +77.3K | 251.4K | +44% | $0 |
| 2021-09-30 | 2021-09-28 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | A - Grant | $0.00 | +6,667 | 180.4K | +4% | $0 | |
| 2021-09-30 | 2021-09-28 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | F - Tax | $6.50 | -2,839 | 177.5K | -2% | -$18.5K |
Purchase Sale Sale after option exercise All abbreviations